Latest News

Quotient Sciences announces the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16th October 2023. Thierry succeeds Mark Egerton who retires after 18 years as CEO with Quotient Sciences. As part of...

Quotient Sciences, a leading global pharmaceutical drug development and manufacturing accelerator, is proud to announce the successful completion of a US Food and Drug Administration (FDA) inspection of its bioanalytical facility in Alnwick...

Nick McEntee, Executive Director, Head of UK GMP Operations at Quotient Sciences discusses strategies for flexible, on-demand manufacture of clinical trial materials (CTMs) with Contract Pharma.Clinical trials are a critical component in dr...

What are the "3 Key Trends" that are shaping the CDMO industry in 2023 and beyond?From integrated drug development services to sterile drug manufacturing, our Executive Director of Commercial, Dr. Eleanor Row, touches on it all in...

Oxilio completes Phase 1 clinical trial with OXL001 at Quotient Sciences - Nottingham with favorable safety and pharmacokinetic data. Also announced, the commencement of an additional pre-clinical program that will enhance understanding of ...